Akso Health Group
6 hedge funds and large institutions have $126K invested in Akso Health Group in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more ownership
Funds ownership: 0.53% → 0.53% (+0%)
1% less capital invested
Capital invested by funds: $128K → $126K (-$1.81K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$6.55K |
| 2 |
HF
HRT Financial
New York
|
+$3.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.34K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$2.27K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$747 |
AHG Hedge Fund Activity: Q2 2023 in Review
6 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Akso Health Group (AHG) for Q2 2023, worth a combined $126K — down 1.4% from $128K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AHG positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was RhumbLine Advisers, opening a new position worth an estimated $6.55K. The largest seller was Renaissance Technologies, cutting an estimated $6.34K.
- 6 institutional investors held Akso Health Group (AHG) as of Q2 2023, up from 5 in Q1 2023.
- Funds reported $126K of Akso Health Group stock for Q2 2023, down 1.4% quarter-over-quarter.
- 2 funds opened new Akso Health Group positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Akso Health Group buyer in Q2 2023 was RhumbLine Advisers, an estimated $6.55K added.
- The largest Akso Health Group seller in Q2 2023 was Renaissance Technologies, an estimated $6.34K sold.
Based on aggregated 13F filings for Q2 2023.